Viking Global’s 5 Long-Term Stock Picks

3. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Stock Held by Viking Global Since: Q2 2019

Percentage of Viking Global’s Portfolio as of Q1 2023: 2.07%

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a California-based biotechnology company specializing in medicines related to genetic diseases and cancers. The company is partnering with the UAE-based healthcare company, Burjeel Holdings, for project NADER (Needs Assessment and Therapeutics Development for Rare Diseases). The project aims to revolutionize early diagnosis and treatment of rare diseases in the MENA region.

Over the last 3 months, seven Wall Street analysts covered BridgeBio Pharma, Inc. (NASDAQ:BBIO) stock and all of them maintain a Buy or Overweight rating with an average price target of $29.50. On July 12, BridgeBio Pharma, Inc. (NASDAQ:BBIO) closed at $18.05.

Viking Global has held BridgeBio Pharma, Inc. (NASDAQ:BBIO) stock since the second quarter of 2019. In Q1 2023, the company represented 2.07% of the investment portfolio with 26.62 million shares worth $441.376 million. Viking Global was also the largest hedge fund holder of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the quarter.

Follow Bridgebio Pharma Inc. (NASDAQ:BBIO)